# US 2010/0167945 A1 · Drug selection for breast cancer therapy using antibody-based arrays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167945 A1
- Document ID: US20100167945A1
- Status: Published application
- Kind: A1
- Application number: 12/511,017
- Filed: 2009-07-28
- Published: 2010-07-01
- Earliest claimed: 2008-02-25
- Assignees: Prometheus Laboratories Inc.
- Inventors: Sharat Singh; Jeanne Harvey; Phillip Kim; Xinjun Liu; Limin Liu; Robert Barham; Bruce Neri
- Web page: https://patentgrep.com/patent/US20100167945A1

## CPC

- G01N 33/57515: of the breast
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.

## Claims

### Claim 1

A method for selecting a suitable anticancer drug for the treatment of a breast tumor, the method comprising:
(a) isolating cells of a breast tumor after administration of an anticancer drug, or prior to incubation with an anticancer drug;
(b) lysing the isolated cells to produce a cellular extract;
(c) detecting an activation state of one or more analytes in the cellular extract using an assay comprising a plurality of dilution series of capture antibodies specific for the one or more analytes, wherein the capture antibodies are restrained on a solid support; and
(d) determining whether the anticancer drug is suitable or unsuitable for the treatment of the breast tumor by comparing the activation state detected for the one or more analytes with a reference activation profile generated in the absence of the anticancer drug.

### Claim 2 (depends on 1)

The method of claim 1, wherein the breast tumor is derived from a subject with ductal carcinoma or lobular carcinoma.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ductal carcinoma is invasive ductal carcinoma or ductal carcinoma in situ.

### Claim 4 (depends on 2)

The method of claim 2, wherein the lobular carcinoma is invasive lobular carcinoma or lobular carcinoma in situ.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cells comprise circulating cells of the breast tumor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the circulating cells are isolated from a sample by immunomagnetic separation.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sample is selected from the group consisting of whole blood, serum, plasma, ductal lavage fluid, nipple aspirate, lymph, bone marrow aspirate, urine, saliva, fine needle aspirate, and combinations thereof.

### Claim 8 (depends on 5)

The method of claim 5, wherein the circulating cells are selected from the group consisting of circulating tumor cells, circulating endothelial cells, circulating endothelial progenitor cells, cancer stem cells, disseminated tumor cells, and combinations thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cells are isolated from tumor tissue.

### Claim 10 (depends on 9)

The method of claim 9, wherein the tumor tissue is primary tumor tissue or metastatic tumor tissue.

### Claim 11 (depends on 9)

The method of claim 9, wherein the cells are isolated from tumor tissue as a fine needle aspirate sample.

### Claim 12 (depends on 1)

The method of claim 1, wherein the isolated cells are stimulated in vitro with growth factors.

### Claim 13 (depends on 1)

The method of claim 1, wherein the anticancer drug is selected from the group consisting of a monoclonal antibody, tyrosine kinase inhibitor, chemotherapeutic agent, hormonal therapeutic agent, radiotherapeutic agent, vaccine, and combinations thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the monoclonal antibody is selected from the group consisting of trastuzumab (Herceptin®), alemtuzumab (Campath®), bevacizumab (Avastin®), cetuximab (Erbitue®), gemtuzumab (Mylotarg®), panitumumab (Vectibix™), rituximab (Rituxan®), tositumomab (BEXXAR®), and combinations thereof.

### Claim 15 (depends on 13)

The method of claim 13, wherein the tyrosine kinase inhibitor is selected from the group consisting of gefitinib (Iressa®), sunitinib (Sutent®), erlotinib (Tarceva®), lapatinib (Tykerb®), canertinib (CI 1033), semaxinib (SU5416), vatalanib (PTK787/ZK222584), sorafenib (BAY 43-9006), imatinib mesylate (Gleevec®), leflunomide (SU101), vandetanib (ZACTIMA™; ZD6474), and combinations thereof.

### Claim 16 (depends on 13)

The method of claim 13, wherein the chemotherapeutic agent is selected from the group consisting of pemetrexed (ALIMTA®), gemcitabine (Gemzar®), sirolimus (rapamycin), rapamycin analogs, platinum compounds, carboplatin, cisplatin, satraplatin, paclitaxel (Taxol®), docetaxel (Taxotere®), temsirolimus (CCI-779), everolimus (RAD001), and combinations thereof.

### Claim 17 (depends on 13)

The method of claim 13, wherein the hormonal therapeutic agent is selected from the group consisting of aromatase inhibitors, selective estrogen receptor modulators, steroids, finasteride, gonadotropin-releasing hormone agonists, pharmaceutically acceptable salts thereof, stereoisomers thereof, derivatives thereof, analogs thereof, and combinations thereof.

### Claim 18 (depends on 13)

The method of claim 13, wherein the radiotherapeutic agent is selected from the group consisting of 47Sc, 64Cu, 67Cu, 89Sr, 86Y, 87Y, 90Y, 105Rh, 111Ag, 111In, 117mSn, 149Pm, 153Sm, 166Ho, 177Lu, 186Re, 188Re, 211At, 212Bi, and combinations thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein the one or more analytes comprise a plurality of signal transduction molecules.

### Claim 20 (depends on 19)

The method of claim 19, wherein the plurality of signal transduction molecules is selected from the group consisting of receptor tyrosine kinases, non-receptor tyrosine kinases, tyrosine kinase signaling cascade components, nuclear hormone receptors, nuclear receptor coactivators, nuclear receptor repressors, and combinations thereof.

### Claim 21 (depends on 19)

The method of claim 19, wherein the plurality of signal transduction molecules is selected from the group consisting of EGFR (ErbB1), HER-2 (ErbB2), p95ErbB2, HER-3 (ErbB3), HER-4 (ErbB4), Raf, SRC, Mek, NFkB-IkB, mTor, PI3K, VEGF, VEGFR-1, VEGFR-2, VEGFR-3, Eph-a, Eph-b, Eph-c, Eph-d, cMet, FGFR, cKit, Flt-3, Tie-1, Tie-2, Flt-3, cFMS, PDGFRA, PDGFRB, Abl, FTL 3, RET, Kit, HGFR, FGFR1, FGFR2, FGFR3, FGFR4, IGF-1R, ER, PR, NCOR, AIB1, and combinations thereof.

### Claim 22 (depends on 19)

The method of claim 19, wherein the plurality of signal transduction molecules is selected from the group consisting of ErbB1, ErbB2, p95ErbB2, ErbB3, ErbB4, VEGFR-1, VEGFR-2, VEGFR-3, ER, PR, and combinations thereof.

### Claim 23 (depends on 1)

The method of claim 1, wherein the activation state is selected from the group consisting of a phosphorylation state, ubiquitination state, complexation state, and combinations thereof.

### Claim 24 (depends on 1)

The method of claim 1, wherein the solid support is selected from the group consisting of glass, plastic, chips, pins, filters, beads, paper, membrane, fiber bundles, and combinations thereof.

### Claim 25 (depends on 1)

The method of claim 1, wherein the capture antibodies are restrained on the solid support in an addressable array.

### Claim 26 (depends on 1)

The method of claim 1, wherein the assay in step (c) comprises:
(i) incubating the cellular extract with the plurality of dilution series of capture antibodies to form a plurality of captured analytes;
(ii) incubating the plurality of captured analytes with activation state-dependent antibodies specific for the corresponding analytes to foam a plurality of detectable captured analytes;
(iii) incubating the plurality of detectable captured analytes with first and second members of a signal amplification pair to generate an amplified signal; and
(iv) detecting the amplified signal generated from the first and second members of the signal amplification pair.

### Claim 27 (depends on 26)

The method of claim 26, wherein the activation state-dependent antibodies comprise a first member of a binding pair.

### Claim 28 (depends on 27)

The method of claim 27, wherein the first member of the binding pair is biotin.

### Claim 29 (depends on 26)

The method of claim 26, wherein the first member of the signal amplification pair comprises a second member of the binding pair.

### Claim 30 (depends on 29)

The method of claim 29, wherein the second member of the binding pair is streptavidin.

### Claim 31 (depends on 29)

The method of claim 29, wherein the first member of the signal amplification pair is a peroxidase.

### Claim 32 (depends on 31)

The method of claim 31, wherein the peroxidase is horseradish peroxidase (HRP).

### Claim 33 (depends on 31)

The method of claim 31, wherein the second member of the signal amplification pair is a tyramide reagent.

### Claim 34 (depends on 33)

The method of claim 33, wherein the tyramide reagent is biotin-tyramide.

### Claim 35 (depends on 34)

The method of claim 34, wherein the amplified signal is generated by peroxidase oxidization of the biotin-tyramide to produce an activated tyramide.

### Claim 36 (depends on 35)

The method of claim 35, wherein the activated tyramide is directly detected.

### Claim 37 (depends on 35)

The method of claim 35, wherein the activated tyramide is detected upon the addition of a signal-detecting reagent.

### Claim 38 (depends on 37)

The method of claim 37, wherein the signal-detecting reagent is a streptavidin-labeled fluorophore.

### Claim 39 (depends on 37)

The method of claim 37, wherein the signal-detecting reagent is a combination of a streptavidin-labeled peroxidase and a chromogenic reagent.

### Claim 40 (depends on 39)

The method of claim 39, wherein the chromogenic reagent is 3,3′,5,5′-tetramethylbenzidine (TMB).

### Claim 41 (depends on 1)

The method of claim 1, wherein the assay in step (c) comprises:
(i) incubating the cellular extract with the plurality of dilution series of capture antibodies to form a plurality of captured analytes;
(ii) incubating the plurality of captured analytes with detection antibodies comprising a plurality of activation state-independent antibodies and a plurality of activation state-dependent antibodies specific for the corresponding analytes to form a plurality of detectable captured analytes,
wherein the activation state-independent antibodies are labeled with a facilitating moiety, the activation state-dependent antibodies are labeled with a first member of a signal amplification pair, and the facilitating moiety generates an oxidizing agent which channels to and reacts with the first member of the signal amplification pair;
(iii) incubating the plurality of detectable captured analytes with a second member of the signal amplification pair to generate an amplified signal; and
(iv) detecting the amplified signal generated from the first and second members of the signal amplification pair.

### Claim 42 (depends on 41)

The method of claim 41, wherein the activation state-independent antibodies are directly labeled with the facilitating moiety.

### Claim 43 (depends on 41)

The method of claim 41, wherein the activation state-independent antibodies are labeled with the facilitating moiety via hybridization between an oligonucleotide conjugated to the activation state-independent antibodies and a complementary oligonucleotide conjugated to the facilitating moiety.

### Claim 44 (depends on 41)

The method of claim 41, wherein the activation state-dependent antibodies are directly labeled with the first member of the signal amplification pair.

### Claim 45 (depends on 41)

The method of claim 41, wherein the activation state-dependent antibodies are labeled with the first member of the signal amplification pair via binding between a first member of a binding pair conjugated to the activation state-dependent antibodies and a second member of the binding pair conjugated to the first member of the signal amplification pair.

### Claim 46 (depends on 45)

The method of claim 45, wherein the first member of the binding pair is biotin.

### Claim 47 (depends on 45)

The method of claim 45, wherein the second member of the binding pair is streptavidin.

### Claim 48 (depends on 41)

The method of claim 41, wherein the facilitating moiety is glucose oxidase.

### Claim 49 (depends on 48)

The method of claim 48, wherein the glucose oxidase and the activation state-independent antibodies are conjugated to a sulfhydryl-activated dextran molecule.

### Claim 50 (depends on 49)

The method of claim 49, wherein the sulfhydryl-activated dextran molecule has a molecular weight of 500 kDa.

### Claim 51 (depends on 48)

The method of claim 48, wherein the oxidizing agent is hydrogen peroxide (H2O2).

### Claim 52 (depends on 51)

The method of claim 51, wherein the first member of the signal amplification pair is a peroxidase.

### Claim 53 (depends on 52)

The method of claim 52, wherein the peroxidase is horseradish peroxidase (HRP).

### Claim 54 (depends on 52)

The method of claim 52, wherein the second member of the signal amplification pair is a tyramide reagent.

### Claim 55 (depends on 54)

The method of claim 54, wherein the tyramide reagent is biotin-tyramide.

### Claim 56 (depends on 55)

The method of claim 55, wherein the amplified signal is generated by peroxidase oxidization of the biotin-tyramide to produce an activated tyramide.

### Claim 57 (depends on 56)

The method of claim 56, wherein the activated tyramide is directly detected.

### Claim 58 (depends on 56)

The method of claim 56, wherein the activated tyramide is detected upon the addition of a signal-detecting reagent.

### Claim 59 (depends on 58)

The method of claim 58, wherein the signal-detecting reagent is a streptavidin-labeled fluorophore.

### Claim 60 (depends on 58)

The method of claim 58, wherein the signal-detecting reagent is a combination of a streptavidin-labeled peroxidase and a chromogenic reagent.

### Claim 61 (depends on 60)

The method of claim 60, wherein the chromogenic reagent is 3,3′,5,5′-tetramethylbenzidine (TMB).

### Claim 62

A method for identifying the response of a breast tumor to treatment with an anticancer drug, the method comprising:
(a) isolating cells of a breast tumor after administration of an anticancer drug, or prior to incubation with an anticancer drug;
(b) lysing the isolated cells to produce a cellular extract;
(c) detecting an activation state of one or more analytes in the cellular extract using an assay comprising a plurality of dilution series of capture antibodies specific for the one or more analytes, wherein the capture antibodies are restrained on a solid support; and
(d) identifying the breast tumor as responsive or non-responsive to treatment with the anticancer drug by comparing the activation state detected for the one or more analytes with a reference activation profile generated in the absence of the anticancer drug.

### Claim at position 63

-80. (canceled)

### Claim 81

A method for predicting the response of a subject having a breast tumor to treatment with an anticancer drug, the method comprising:
(a) isolating cells of a breast tumor after administration of an anticancer drug, or prior to incubation with an anticancer drug;
(b) lysing the isolated cells to produce a cellular extract;
(c) detecting an activation state of one or more analytes in the cellular extract using an assay comprising a plurality of dilution series of capture antibodies specific for the one or more analytes, wherein the capture antibodies are restrained on a solid support; and
(d) predicting the likelihood that the subject will respond to treatment with the anticancer drug by comparing the activation state detected for the one or more analytes with a reference activation profile generated in the absence of the anticancer drug.

### Claim at position 65

-99. (canceled)

### Claim 100

An array having superior dynamic range comprising a plurality of dilution series of capture antibodies restrained on a solid support, wherein the capture antibodies in each dilution series are specific for one or more analytes corresponding to a component of a signal transduction pathway in a cellular extract.

### Claim at position 67

-104. (canceled)

### Claim 105

A method for detecting the presence of a truncated receptor, said method comprising:
(a) incubating a cellular extract with a plurality of beads specific for an extracellular domain (ECD) binding region of a full-length receptor;
(b) removing said plurality of beads from said cellular extract, thereby removing said full-length receptor to form a cellular extract devoid of said full-length receptor;
(c) incubating said cellular extract devoid of said full-length receptor with a plurality of capture antibodies, wherein said plurality of capture antibodies is specific for an intracellular domain (ICD) binding region of said truncated receptor and wherein said plurality of capture antibodies is restrained on a solid support to foam a plurality of captured truncated receptors;
(d) incubating the plurality of captured truncated receptors with detection antibodies specific for the corresponding truncated receptors to form a plurality of detectable captured truncated receptors;
(e) incubating the plurality of detectable captured truncated receptors with first and second members of a signal amplification pair to generate an amplified signal; and
(f) detecting an amplified signal generated from the first and second members of the signal amplification pair.

### Claim at position 69

-134. (canceled)

### Claim 135

A method for detecting the presence of a truncated receptor, said method comprising:
(a) incubating a cellular extract with a plurality of beads specific for an extracellular domain (ECD) binding region of a full-length receptor;
(b) removing said plurality of beads from said cellular extract, thereby removing said full-length receptor to form a cellular extract devoid of said full-length receptor;
(c) incubating said cellular extract devoid of said full-length receptor with a plurality of capture antibodies, wherein said plurality of capture antibodies is specific for an intracellular domain (ICD) binding region of said truncated receptor and wherein said plurality of capture antibodies is restrained on a solid support to form a plurality of captured truncated receptors;
(d) incubating the plurality of captured truncated receptors with detection antibodies comprising a plurality of activation state-independent antibodies and a plurality of activation state-dependent antibodies specific for the corresponding truncated receptors to form a plurality of detectable captured truncated receptors,
wherein the activation state-independent antibodies are labeled with a facilitating moiety, the activation state-dependent antibodies are labeled with a first member of a signal amplification pair, and the facilitating moiety generates an oxidizing agent which channels to and reacts with the first member of the signal amplification pair;
(e) incubating the plurality of detectable captured truncated receptors with a second member of the signal amplification pair to generate an amplified signal; and
(f) detecting the amplified signal generated from the first and second members of the signal amplification pair.

### Claim at position 71

-168. (canceled)
